Since 2017, Omico has been involved in 101 publications



118 Ballinger, M. L., Pattnaik, S., Mundra, P. A., Zaheed, M., Rath, E., Priestley, P., … & Nicolas, G. (2023). Heritable defects in telomere and mitotic function selectively predispose to sarcomas. Science379(6629), 253-260.
117 Collet L, Telouk P, Albarede F, et al. Connecting the changing metallomic spectrum and survival in sarcoma: a pilot study. Research Square; 2023. DOI: 10.21203/
116 Gianferante DM, Moore A, Spector LG, Wheeler W, Yang T, Hubbard A, Gorlick R, Patiño-Garcia A, Lecanda F, Flanagan AM, Amary F, Andrulis IL, Wunder JS, Thomas DM, Ballinger ML, Serra M, Hattinger C, Demerath E, Johnson W, Birmann BM, De Vivo I, Giles G, Teras LR, Arslan A, Vermeulen R, Sample J, Freedman ND, Huang WY, Chanock SJ, Savage SA, Berndt SI, Mirabello L. Genetically inferred birthweight, height, and puberty timing and risk of osteosarcoma. Cancer Epidemiol. 2023 Aug 16:102432. doi: 10.1016/j.canep.2023.102432. Epub ahead of print. PMID: 37596165.
115 Harrison C, Bartley N, Jacobs C, Best M, Vatter S, Meiser B, Ballinger ML, Thomas DM, Butow P; members of the PiGeOn Project. Family communication and results disclosure after germline sequencing: A mixed methods study. Patient Educ Couns. 2023 May 19;114:107800. doi: 10.1016/j.pec.2023.107800. Epub ahead of print. PMID: 37210765.
114 Kansara, M., Bhardwaj, N., Thavaneswaran, S., Xu, C., Lee, J. K., Chang, L. B., … & Thomas, D. M. (2023). Early circulating tumor DNA dynamics as a pan‐tumor biomarker for long‐term clinical outcome in patients treated with durvalumab and tremelimumab. Molecular Oncology17(2), 298-311.
113 Le Tourneau C, André F, Helland Å, Mileshkin L, Minnaard W, Schiel A, Taskén K, Thomas DM, Veronese ML, Durán-Pacheco G, Leyens L, Rufibach K, Thomas M, Krämer A. Modified study designs to expand treatment options in personalised oncology: a multistakeholder view. Eur J Cancer. 2023 Aug 4;194:113278. doi: 10.1016/j.ejca.2023.113278. Epub ahead of print. PMID: 37820553.
112 Lu, C. Y., Terry, V., & Thomas, D. M. (2023). Precision medicine: affording the successes of science. NPJ Precision Oncology7(1), 3.
111 Mersiades AJ, Solomon BJ, Thomas DM, Lee CK, Cummins MM, Sebastian L, Ballinger ML, Collignon E, Turnbull OM, Yip S, Morton RL, Brown C, Wheeler PJ, Itchins M, Simes RJ, Pavlakis N. ASPiRATION: Australian observational cohort study of comprehensive genomic profiling in metastatic lung cancer tissue. Future Oncol. 2023 Sep 28. doi: 10.2217/fon-2023-0366. Epub ahead of print. PMID: 37767626.
110 Ng JY, Warwick L, Craft P, Austen L, Ashford B, Gorddard N, Ballinger ML, Thomas DM, Blombery P, Tucker K, Polizzotto MN. Myelodysplastic syndrome and multiple solid tumours in an individual with compound heterozygous deleterious FANCM variants: A case report and review of the literature. Br J Haematol. 2023 Aug 22. doi: 10.1111/bjh.19059. Epub ahead of print. PMID: 37608704.
109 Sabesan S, Malica M, Gebbie C, Scott C, Thomas D, Zalcberg J. Implementation of the Australasian Teletrial Model: Translating ideas into action using implementation science frameworks. J Telemed Telecare. 2023 Sep;29(8):641-647. doi: 10.1177/1357633X211017805. Epub 2021 Jul 7. PMID: 34233548.
108 Sharaf R, Jin DX, Grady J, Napier C, Ebot E, Frampton GM, Albacker LA, Thomas DM, Montesion M. A pan-sarcoma landscape of telomeric content shows that alterations in RAD51B and GID4 are associated with higher telomeric content. NPJ Genom Med. 2023 Sep 14;8(1):26. doi: 10.1038/s41525-023-00369-6. PMID: 37709802; PMCID: PMC10502097.
107 Stacchiotti S, Maria Frezza A, Demetri GD, Blay JY, Bajpai J, Baldi GG, …Thomas DM, …. Retrospective observational studies in ultra-rare sarcomas: A consensus paper from the Connective Tissue Oncology Society (CTOS) community of experts on the minimum requirements for the evaluation of activity of systemic treatments. Cancer Treat Rev. 2022 Nov;110:102455. doi: 10.1016/j.ctrv.2022.102455. Epub 2022 Aug 18. PMID: 36031697.
106 Stark, Z., Boughtwood, T., Haas, M., Braithwaite, J., Gaff, C. L., Goranitis, I., .. Thomas, D.. & North, K. N. (2023). Australian Genomics: Outcomes of a 5-year national program to accelerate the integration of genomics in healthcare. The American Journal of Human Genetics110(3), 419-426.
105 Thavaneswaran, S., Kansara, M., Lin, F. et al. A signal-seeking Phase 2 study of olaparib and durvalumab in advanced solid cancers with homologous recombination repair gene alterations. Br J Cancer 1-11 (2023).
104 Vaghjiani VG, Cochrane CR, Jayasekara WSN, Chong WC, Szczepny A, Kumar B, Martelotto LG, McCaw A, Carey K, Kansara M, Thomas DM, Walkley C, Mudge S, Gough DJ, Downie PA, Peacock CD, Matsui W, Watkins DN, Cain JE. Ligand-dependent hedgehog signaling maintains an undifferentiated, malignant osteosarcoma phenotype. Oncogene. 2023 Nov;42(47):3529-3541. doi: 10.1038/s41388-023-02864-7. Epub 2023 Oct 16. PMID: 37845394; PMCID: PMC10656285.
103 Walpole, IR, Zaman FY, Zhao P, Marshall VM, Lin FP, Thomas DM, et al. Computational repurposing of oncology drugs through off-target drug binding interactions from pharmacological databases bioRxiv, 2023.07. 01.547311
102 Zeverijn LJ, Looze EJ, Thavaneswaran S, van Berge Henegouwen JM, Simes RJ, Hoes LR, Sjoquist KM, van der Wijngaart H, Sebastian L, Geurts BS, Lee CK, de Wit GF, Espinoza D, Roepman P, Lin FP, Jansen AML, de Leng WWJ, van der Noort V, Leek LVM, de Vos FYFL, van Herpen CML, Gelderblom H, Verheul HMW, Thomas DM, Voest EE. Limited clinical activity of palbociclib and ribociclib monotherapy in advanced cancers with cyclin D-CDK4/6 pathway alterations in the Dutch DRUP and Australian MoST trials. Int J Cancer. 2023 Oct 1;153(7):1413-1422. doi: 10.1002/ijc.34649. Epub 2023 Jul 10. PMID: 37424386.



101 Woodford R, Prather L, Helfer C, Davey L, Penas-Prado M, Armstrong T, Tucker K, Aldape K, Gilbert M, Clark C, Thavaneswaran S, Wang D, Mandel J, Kasherman L. Malignant melanocytic schwannian tumor and leptomeningeal disease: A case series with a focus on management. J Neurol Sci 2022.
99 Vatter S, Schlub TE, Napier CE, Best MC, Bartley N, Juraskova I, Meiser B, Ballinger ML, Biesecker BB, Goldstein D, Thomas DM, Butow P; Members of the PiGeOn Project. Psychological outcomes in advanced cancer patients after receiving genomic tumor profiling results. Health Psychol. 2022 Jun;41(6):396-408. doi: 10.1037/hea0001181. PMID: 35604703.
97 Thavaneswaran S, Lin FP, Kansara M, Grady JP, Espinoza D, Joshua AM, Grimison P, Craft P , Cosman R, Lee C, Harwood K, Chinchen S, Corpuz T, Ballinger M, Sebastian L, Simes J, Thomas D. A signal-seeking Phase II trial of Durvalumab and Tremelimumab Focused on Advanced, Rare and Less Common Cancers. medrxiv 2022. doi:
89 Jadhao S, Davison C, Roulis EV, Lee S, Lacaze P, Riaz M, McNeil JJ, Thomas DM, Pecheniuk NM, Hyland CA, Flower RL, Nagaraj SH. Using whole-genome sequencing to characterize clinically significant blood groups among healthy older Australians. Blood Adv. 2022 Aug 9;6(15):4593-4604. doi: 10.1182/bloodadvances.2022007505. PMID: 35420653.
88 Husereau, D., Steuten, L., Muthu, V., Thomas, D.M., Spinner, D.S., Ivany, C., Mengel, M., Sheffield, B., Yip, S., Jacobs, P. and Sullivan, T., 2022. Effective and Efficient Delivery of Genome-Based Testing-What Conditions Are Necessary for Health System Readiness? Healthcare (Basel, Switzerland), 10(10), p.2086.
87 Gounder, M.M., Agaram, N.P., Trabucco, S.E. et al. Clinical genomic profiling in the management of patients with soft tissue and bone sarcoma. Nat Commun 13, 3406 (2022).
86 Best M, Napier C, Schlub T, Bartley N, Biesecker B, Ballinger M, Butow P. Validation of the multidimensional impact of Cancer Risk Assessment Questionnaire to assess impact of waiting for genome sequencing results. Psychooncology. 2022 Jul;31(7):1204-1211. doi: 10.1002/pon.5908. Epub 2022 Mar 1. PMID: 35194887.
85 Thomas DM. Heritable defects in telomere and mitotic function selectively predispose to sarcomas. Cancer Science vol. 113; 111 River St, Hoboken 07030-5774, NJ USA: WILEY.
84 Meiser B, Butow P, Davies G, Napier CE, Schlub TE, Bartley N, Juraskova I, Ballinger ML, Thomas DM, Best MC, Psychological predictors of cancer patients’ and their relatives’ attitudes towards the return of genomic sequencing results. European Journal of Medical Genetics 65 (6), 104516
83 Mateo J, Steuten L, Aftimos P, André F, Davies M, Garralda E, Geissler J, Husereau D, Martinez-Lopez I, Normanno N, Reis-Filho JS, Stefani S, Thomas DM, Westphalen CB, Voest E. Delivering precision oncology to patients with cancer. Nature Medicine 28 (4), 658-665
82 Lacaze PA, Tiller J, Winship I, DNA Screen Investigator Group, Lacaze P, Tiller J, Winship I, Brotchie A, McNeil J, Zalcberg J, David Thomas D, et al., Population DNA screening for medically actionable disease risk in adults. Medical Journal of Australia 216 (6), 278-280
81 Butow P, Davies G, Napier CE, Bartley N, Ballinger ML, Biesecker B, etal., Value of whole‐genome sequencing to Australian cancer patients and their first degree relatives participating in a genomic sequencing study. Journal of Genetic Counseling 31 (1), 96-108
80 Butow P, Best MC, Davies G, Schlub T, Napier CE, N Bartley N, et al., Psychological impact of comprehensive tumor genomic profiling results for advanced cancer patients. Patient Education and Counseling
79 Best MC, Butow P, Savard J, Jacobs C, Bartley N, Davies G, Napier CE, Ballinger ML, Thomas DM, Biesecker B, Tucker KM, Juraskova I, Meiser B, Schlub T, Newson AJ. Preferences for return of germline genome sequencing results for cancer patients and their genetic relatives in a research setting. European Journal of Human Genetics, 1-8
78 Best M, Bartley N, Napier CE, Fisher A, Ballinger ML, Thomas DM, Goldstein D, Tucker KM, Biesecker B, Butow P. Return of comprehensive tumour genomic profiling results to advanced cancer patients: a qualitative study. Support Care Cancer 30, 8201–8210 (2022).


77 Willis AM, Smith SK, Meiser B, James PA, Ballinger ML, Thomas DM, Yanes T, Young MA. Influence of lived experience on risk perception among women who received a breast cancer polygenic risk score: ‘Another piece of the pie’. J Genet Couns. 2021 Jun;30(3):849-860. doi: 10.1002/jgc4.1384. Epub 2021 Jan 19. PMID: 33470033.
76 Vatter S, Bartley, Nicci MA, Best M, Juraskova I, Jacobs C, Ballinger ML, Thomas DM, Butow, P. Does undertaking genome sequencing prompt actual and planned lifestyle-related behavior change in cancer patients and survivors? A qualitative study, Journal of Psychosocial Oncology Research and Practice: July-September 2021 – Volume 3 – Issue 3 – p e059 doi: 10.1097/OR9.0000000000000059
75 Thomas DM, Hackett JM, Plestina S. Unlocking Access to Broad Molecular Profiling: Benefits, Barriers, and Policy Solutions. Public Health Genomics. 2021 Dec 27:1-10. doi: 10.1159/000520000. Epub ahead of print. PMID: 34959236.
74 Thavaneswaran, S., Ballinger, M., Butow, P., Meiser, B., Goldstein, D., Lin, F., Napier, C., Thomas, D., & Best, M. (2021). The experiences and needs of Australian medical oncologists in integrating comprehensive genomic profiling into clinical care: a nation-wide survey. Oncotarget, 12(21), 2169–2176.
73 Sylvester DE, Chen Y, Grima N, Saletta F, Padhye B, Bennetts B, Wright D, Krivanek M, Graf N, Zhou L, Catchpoole D, Kirk J, Latchoumanin O, Qiao L, Ballinger M, Thomas D, Jamieson R, Dalla-Pozza L, Byrne JA. Rare germline variants in childhood cancer patients suspected of genetic predisposition to cancer. Genes Chromosomes Cancer. 2022 Feb;61(2):81-93. doi: 10.1002/gcc.23006. Epub 2021 Oct 30. PMID: 34687117.
72 Stacchiotti S, Frezza AM, Blay JY, Baldini EH, Bonvalot S, Bovée JVMG, Callegaro D, Casali PG, Chiang RC, Demetri GD, Demicco EG, Desai J, Eriksson M, Gelderblom H, George S, Gounder MM, Gronchi A, Gupta A, Haas RL, Hayes-Jardon A, Hohenberger P, Jones KB, Jones RL, Kasper B, Kawai A, Kirsch DG, Kleinerman ES, Le Cesne A, Lim J, Chirlaque López MD, Maestro R, Marcos-Gragera R, Martin Broto J, Matsuda T, Mir O, Patel SR, Raut CP, Razak ARA, Reed DR, Rutkowski P, Sanfilippo RG, Sbaraglia M, Schaefer IM, Strauss DC, Sundby Hall K, Tap WD, Thomas DM, van der Graaf WTA, van Houdt WJ, Visser O, von Mehren M, Wagner AJ, Wilky BA, Won YJ, Fletcher CDM, Dei Tos AP, Trama A. Ultra-rare sarcomas: A consensus paper from the Connective Tissue Oncology Society community of experts on the incidence threshold and the list of entities. Cancer, 127(16), 2934–2942. Apr 28. doi: 10.1002/cncr.33618. Epub ahead of print. PMID: 33910263.
71 Smit AK, Bartley N, Best MC, Napier CE, Butow P, Newson AJ, Tucker K, Ballinger ML, Thomas DM, Jacobs C, Meiser B, Goldstein D, Savard J, Juraskova I; PiGeOn authorship group. Family communication about genomic sequencing: A qualitative study with cancer patients and relatives. Patient Educ Couns. 2021 May;104(5):944-952. doi: 10.1016/j.pec.2020.10.022. Epub 2020 Oct 20. PMID: 33129629.
70 Singhal D, Hahn CN, Feurstein S, Wee LYA, Moma L, Kutyna MM, Chhetri R, Eshraghi L, Schreiber AW, Feng J, Wang PP, Babic M, Parker WT, Gao S, Moore S, Das S, Thomas D, Pattnaik S, Brown AL, D’Andrea RJ, Poplawski NK, Thomas D, Scott HS, Godley LA, Hiwase DK. Targeted gene panels identify a high frequency of pathogenic germline variants in patients diagnosed with a hematological malignancy and at least one other independent cancer. Leukemia. 2021 Apr 13. doi: 10.1038/s41375-021-01246-w. Epub ahead of print. PMID: 33850299.
69 Scheinberg T, Lomax A, Tattersall M, Thomas D, McCowage G, Sullivan M, Karim R, Luk PP, Mahar A, Bonar F, Bhadri VA. PD-1 blockade using pembrolizumab in adolescent and young adult patients with advanced bone and soft tissue sarcoma. Cancer Rep (Hoboken). 2021 Apr;4(2):e1327. doi: 10.1002/cnr2.1327. Epub 2020 Dec 13. PMID: 33314769.
68 Sabesan S, Malica M, Gebbie C, Scott C, Thomas D, Zalcberg J. Implementation of the Australasian Teletrial Model: Translating idea into action using implementation science frameworks. J Telemed Telecare. 2021 Jul 7:1357633X211017805. doi: 10.1177/1357633X211017805. Epub ahead of print. PMID: 34233548.
67 Napier CE, Davies G, Butow PN, Schlub TE, Best MC, Bartley N, Juraskova I, Meiser B, Tucker KM, Biesecker BB, Thomas DM, Ballinger ML; Members of the PiGeOn Project. Cancer patient knowledge about and behavioral intentions after germline genome sequencing. Patient Educ Couns. 2021 Jul 7:S0738-3991(21)00439-0. doi: 10.1016/j.pec.2021.07.004. Epub ahead of print. PMID: 34247865.
66 Mweempwa A, Xu H, Vissers JHA, Tothill RW, Pattison AD, Fellowes AP, Thomas DM, Richardson G, Hicks RJ, Grimmond SM, Fox SB, Luen SJ, Desai J, Solomon BJ. Novel RET Fusion RET-SEPTIN9Predicts Response to Selective RET Inhibition With Selpercatinib in Malignant Pheochromocytoma. JCO Precis Oncol. 2021 Nov;5:1160-1165. doi: 10.1200/PO.21.00127. PMID: 34994633.
65 Minoche AE, Lundie B, Peters GB, Ohnesorg T, Pinese M, Thomas DM, Zankl A, Roscioli T, Schonrock N, Kummerfeld S, Burnett L, Dinger ME, Cowley MJ. ClinSV: clinical grade structural and copy number variant detection from whole genome sequencing data. Genome Med. 2021 Feb 25;13(1):32. doi: 10.1186/s13073-021-00841-x. PMID: 33632298; PMCID: PMC7908648.
64 Meiser B, Butow P, Davies G, Napier CE, Schlub TE, Bartley N, Juraskova I, Ballinger ML, Thomas DM, Tucker K, Goldstein D, Biesecker BB, Best MC; Members of the Psychosocial Issues in Genomics in Oncology (PiGeOn) Project. Psychological predictors of advanced cancer patients’ preferences for return of results from comprehensive tumor genomic profiling. Am J Med Genet A. 2021 Nov 10. doi: 10.1002/ajmg.a.62563. Epub ahead of print. PMID: 34755933.
63 Lin FP, Thavaneswaran S, Grady JP, Ballinger M, Kansara M, Oakes SR, Desai J, Lee CK, Simes J, Thomas DM. Criteria-based curation of a therapy-focused compendium to support treatment recommendations in precision oncology. NPJ Precis Oncol. 2021 Jun 23;5(1):58. doi: 10.1038/s41698-021-00194-z. PMID: 34162978.
62 Lau LMS, Mayoh C, Xie J, Barahona P, MacKenzie KL, Wong M, Kamili A, Tsoli M, Failes TW, Kumar A, Mould EVA, Gifford A, Chow SO, Pinese M, Fletcher JI, Arndt GM, Khuong-Quang DA, Wadham C, Eden G, Trebilcock P, Joshi S, Alfred S, Gopalakrishnan A, Khan A, Grebert Wade D, Strong PA, Manouvrier E, Morgan LT, Cadiz R, Ung C, Thomas DM, Tucker KM, Warby M, McCowage GB, Dalla-Pozza L, Byrne JA, Saletta F, Fellowes A, Fox SB, Norris MD, Tyrrell V, Trahair TN, Lock RB, Cowley MJ, Ekert PG, Haber M, Ziegler DS, Marshall GM. In vitro and in vivo drug screens of tumor cells identify novel therapies for high-risk child cancer. EMBO Mol Med. 2021 Dec 20:e14608. doi: 10.15252/emmm.202114608. Epub ahead of print. PMID: 34927798.
61 Kaur S, Sikta N, Schafferhans A, Bordin N, Cowley MJ, Thomas DM, Ballinger ML, O’Donoghue SL., Streamlined use of protein structures in variant analysis. bioRxiv 2021.09.10.459756; doi:
60 Jadhao S, Davison C, Roulis E, Lee S, Lacaze P, Riaz M, McNeil JJ, Thomas DM, Pecheniuk NM, Hyland CA, Flower RL, Nagaraj S, Using Whole Genome Sequencing to Characterize Clinically Significant Blood Groups Among Healthy Older Australians. medRxiv 2021.04.18.21255241; doi:
59 Gong B, Li D, Kusko R, Novoradovskaya N, Zhang Y, Wang S, Pabón-Peña C, Zhang Z, Lai K, Cai W, LoCoco JS, Lader E, Richmond TA, Mittal VK, Liu LC, Johann DJ Jr, Willey JC, Bushel PR, Yu Y, Xu C, Chen G, Burgess D, Cawley S, Giorda K, Haseley N, Qiu F, Wilkins K, Arib H, Attwooll C, Babson K, Bao L, Bao W, Lucas AB, Best H, Bhandari A, Bisgin H, Blackburn J, Blomquist TM, Boardman L, Burgher B, Butler DJ, Chang CJ, Chaubey A, Chen T, Chierici M, Chin CR, Close D, Conroy J, Coleman JC, Craig DJ, Crawford E, Del Pozo A, Deveson IW, Duncan D, Eterovic AK, Fan X, Foox J, Furlanello C, Ghosal A, Glenn S, Guan M, Haag C, Hang X, Happe S, Hennigan B, Hipp J, Hong H, Horvath K, Hu J, Hung LY, Jarosz M, Kerkhof J, Kipp B, Kreil DP, Łabaj P, Lapunzina P, Li P, Li QZ, Li W, Li Z, Liang Y, Liu S, Liu Z, Ma C, Marella N, Martín-Arenas R, Megherbi DB, Meng Q, Mieczkowski PA, Morrison T, Muzny D, Ning B, Parsons BL, Paweletz CP, Pirooznia M, Qu W, Raymond A, Rindler P, Ringler R, Sadikovic B, Scherer A, Schulze E, Sebra R, Shaknovich R, Shi Q, Shi T, Silla-Castro JC, Smith M, López MS, Song P, Stetson D, Strahl M, Stuart A, Supplee J, Szankasi P, Tan H, Tang LY, Tao Y, Thakkar S, Thierry- Mieg D, Thierry-Mieg J, Thodima VJ, Thomas D, Tichý B, Tom N, Garcia EV, Verma S, Walker K, Wang C, Wang J, Wang Y, Wen Z, Wirta V, Wu L, Xiao C, Xiao W, Xu S, Yang M, Ying J, Yip SH, Zhang G, Zhang S, Zhao M, Zheng Y, Zhou X, Mason CE, Mercer T, Tong W, Shi L, Jones W, Xu J. Cross-oncopanel study reveals high sensitivity and accuracy with overall analytical performance depending on genomic regions. Genome Biol. 2021 Apr 16;22(1):109. doi: 10.1186/s13059-021-02315-0. PMID: 33863344; PMCID: PMC8051090.
58 Cilento MA, Poplawski NK, Paramasivam S, Thomas DM, Kichenadasse G. Germline PALB2 Variants and PARP Inhibitors in Endometrial Cancer. J Natl Compr Canc Netw. 2021 Nov;19(11):1212-1217. doi: 10.6004/jnccn.2021.7067. PMID: 34781271.
57 Butow P, Müller F, Napier CE, Bartley N, Ballinger ML, B Biesecker B, Juraskova I, Meiser B, Schlub TE, Thomas DM, Goldstein D, Best M, Members of the PiGeOn Project. Longitudinal patterns in fear of cancer progression in patients with rare, advanced cancers undergoing comprehensive tumour genomic profiling. Psycho‐Oncology 2021 30 (11), 1920-1929.
56 Butow P, Davies G, Napier CE, Bartley N, Ballinger ML, Biesecker B, Juraskova I, Meiser B, Schlub T, Thomas DM, Goldstein D, Best MC; Members of the PiGeOn Project. Value of whole-genome sequencing to Australian cancer patients and their first-degree relatives participating in a genomic sequencing study. J Genet Couns. 2021 Jul 3. doi: 10.1002/jgc4.1455. Epub ahead of print. PMID: 34218500.
55 Bartley N, Davies G, Butow P, Napier CE, Schlub T, Ballinger ML, Thomas DM, Juraskova I, Meiser B, Best MC. Fear of cancer recurrence in patients undergoing germline genome sequencing. Support Care Cancer. 2021 May 25. doi: 10.1007/s00520-021-06311-9. Epub ahead of print. PMID: 34036439.
54 Bartley N, Best MC, Biesecker BB, Fisher A, Goldstein D, Meiser B, Thomas DM, Ballinger ML, Butow P. Effectively communicating comprehensive tumor genomic profiling results: Mitigating uncertainty for advanced cancer patients. Patient Educ Couns. 2021 May 14:S0738-3991(21)00347-5. doi: 10.1016/j.pec.2021.05.018. Epub ahead of print. PMID: 34016496.
53 Alcindor T, Dumitra S, Albritton K, Thomas DM. Disparities in Cancer Care: The Example of Sarcoma-In Search of Solutions for a Global Issue. Am Soc Clin Oncol Educ Book. 2021 Mar;41:1-7. doi: 10.1200/EDBK_320463. PMID: 33770458.


52 Pinese M, Lacaze P, Rath EM, Stone A, Brion MJ, Ameur A, Nagpal S, Puttick C, Husson S, Degrave D, Cristina TN, Kahl VFS, Statham AL, Woods RL, McNeil JJ, Riaz M, Barr M, Nelson MR, Reid CM, Murray AM, Shah R.C, Wolfe R, Atkins JR, Fitzsimmons C, Cairns HM, Green MJ, Carr VJ, Cowley MJ, Pickett HA, James PA, Powell JE, Kaplan W, Gibson G, Gyllensten U, Cairns MJ, McNamara M, Dinger ME, Thomas DM. 2020 The Medical Genome Reference Bank contains whole genome and phenotype data of 2570 healthy elderly. Nat Commun, 11: 435
51 Best M, Butow P, Jacobs C, Juraskova I, Savard J, Meiser B, Goldstein D, Ballinger ML, Bartley N, Napier C, Davies G, Thomas DM, Tucker K, Schlub T, Newson AJ and members of the PiGeOn Project. Advanced cancer patient preferences for receiving molecular profiling results. Psycho-Oncology 2020 16 June 2020 doi: 10.1002/pon.5446
50 Cipponi A, Goode DL, Bedo J, McCabe MJ, Pajic M, Gonzalez-Rajal A, Croucher DR, Junankar S, Saunders DN, Lobachevsky P, Papenfuss AT, Nessem D, Nobis M, Warren SC, Timpson P, Cowley M, Vargas AC, Qiu MR, Generali DG, Keerthikumar S, Nguyen U, Corcoran NM, Long GV, Blay J-Y, Thomas DM. MTOR signaling orchestrates stress-induced mutagenesis facilitating adaptive evolution in human cancers. Science 2020 368: 1127-1131. [IF – 41.06]
49 Caron O, Thomas DM, World Health Organisation Classification of Tumours – Thoracic Tumours, 5th Edition, Li Fraumeni Syndrome, 2020, In press (book chapter)
48 Best MC, Butow P, Jacobs C, Savard J, Biesecker B, Ballinger ML, Bartley N, Davies G, Napier CE, Smit AK, Thomas DM, Newson AJ. Members of the PiGeOn Project.Who should access germline genome sequencing? A mixed methods study of patient views. Clin Genet. 2020 Feb;97(2):329-337. doi: 10.1111/cge.13664. Epub 2019 Nov 26.
47 Shin SJ, Dodd-Eaton EB, Peng G, Bojadzieva J, Chen J, Amos CI, Frone MN, Khincha PP, Mai PL, Savage SA, Ballinger ML, Thomas DM, Yuan Y, Strong LC, Wang W.Penetrance of Different Cancer Types in Families with Li-Fraumeni Syndrome: A Validation Study Using Multicenter Cohorts. Cancer Res. 2020 Jan 15;80(2):354-360. doi: 10.1158/0008-5472.CAN-19-0728. Epub 2019 Nov 12.
46 Dancsok AR, Gao D, Lee AF, Steigen SE, Blay JY, Thomas DM, Maki RG, Nielsen TO, Demicco EG. Tumor-associated macrophages and macrophage-related immune checkpoint expression in sarcomas. Oncoimmunology. 2020 Apr 12;9(1):1747340. doi: 10.1080/2162402X.2020.1747340.
45 Kovac M, Woolley C, Ribi S, Blattmann C, Roth E, Morini M, Kovacova M, Ameline B, Kulozik A, Bielack S, Hartmann W, Ballinger ML, Thomas DM, Tomlinson I, Nathrath M, Heinimann K, Baumhoer D.J Germline RETvariants underlie a subset of paediatric osteosarcoma. Med Genet. 2020 Mar 16:jmedgenet-2019-106734. doi: 10.1136/jmedgenet-2019-106734. Online ahead of print.
44 Kalachand RD, Stordal B, Madden S, Chandler B, Cunningham J, Goode EL, Ruscito I, Braicu EI, Sehouli J, Ignatov A, Yu H, Katsaros D, Mills GB, Lu KH, Carey MS, Timms KM, Kupryjanczyk J, Rzepecka IK, Podgorska A, McAlpine JN, Swisher EM, Bernards SS, O’Riain C, O’Toole S, O’Leary JJ, Bowtell DD, Thomas DM, Prieske K, Joosse SA, Woelber L, Chaudhry P, Häfner N, Runnebaum IB, Hennessy BT. BRCA1 promoter methylation and clinical outcomes in ovarian cancer: an individual patient data meta-analysis. J Natl Cancer Inst. 2020 May 15:djaa070. doi: 10.1093/jnci/djaa070.
43 Davies G, Butow P, Napier CE, Bartley, N, Juraskova I, Meiser B, Ballinger ML, Thomas DM, Schlub TE, Best M. 2020. Advanced cancer patient knowledge of and attitudes towards tumor molecular profiling. Translational Oncology 13: 100799.
42 Butow P, Davies G, Napier C, Bartley N, Juraskova I, Meiser B, Ballinger ML, Schlub T, Thomas DM, Goldstein D, Best MC and members of the PiGeOn Project. Value of Tumor Mutation Profiling to Cancer Patients: An Investigation using the Willingness-To-Pay Technique. JAMA Network Open 2020 3: e204721.
41 Bartley N, Best M, Jacobs C, Juraskova I, Newson A, Savard J, Meiser B, Ballinger ML, Thomas DM, Biesecker B, Butow P. Cancer patients’ views and understanding of genome sequencing: a qualitative study. J Med Genet 2020 in press.
40 Mirabello L, Zhu B, Koster R, Karlins E, Dean M, Yeager M, Gianferante M, Spector LG, Morton LM, Karyadi D, Robison LL, Armstrong GT, Bhatia S, Song L, Pankratz N, Pinheiro M, Gastier-Foster JM, Gorlick R, de Toledo SRC, Petrilli AS, Patino-Garcia A, Lecanda F, Gutierrez-Jimeno M, Serra M, Hattinger C, Picci P, Scotlandi K, Flanagan AM, Tirabosco R, Amary MF, Kurucu N, Ilhan IE, Ballinger ML, Thomas DM, Barkauskas DA, Mejia-Baltodano G, Valverde P, Hicks BD, Zhu B, Wang M, Hutchinson AA, Tucker M, Sampson J, Landi MT, Freedman ND, Gapstur S, Carter B, Hoover RN, Chanock SJ, Savage SA. Pathogenic germline variants in cancer-susceptibility genes in osteosarcoma patients. JAMA Oncology 2020 6: 724-734
39 Seung Jun Shin, Elissa Dodd-Eaton, Gang Peng, Jasmina Bojadzieva, Jingxiao Chen, Christopher Amos, Megan Frone, Payal Khincha, Phuong Mai, Sharon Savage, Mandy Ballinger, David Thomas, Ying Yuan, Louise Strong, and Wenyi Wang (2020). Penetrance of different cancer types in families with Li-Fraumeni syndrome: a validation study using multi-center cohorts. Cancer Research 80:354–60


38 Yanes T, Willis AM, Meiser B, Tucker KM, Best M. (2019). Psychological and behavioural outcomes of genomic testing in cancer: a systematic review. European Journal of Human Genetics; 27 : 28-35.
37 Vargas, A.C., Selinger, C., Satgunaseelan, L., Cooper, W.A., Gupta, R., Stalley, P., Brown, W., Soper, J., Schatz, J., Boyle, R., Thomas, D.M., Tattersall, M.H.N., Bhadri, V., Maclean, F., Bonar, S.F., Scolyer, R.A., Karim, R.Z., McCarthy, S.W., Mahar, A., O’Toole, S.A. (2019). FISH analysis of selected soft tissue tumors: Diagnostic experience in a tertiary center. Asia Pac J Clin Oncol, 15: 38-47.
36 Kansara, M., Thomson, K., Pang, P., Dutour, A., Mirabello, L., Acher, F., Pin, J.P., Demicco, E.G., Yan, J., Teng, M.W.L., Smyth, M.J., Thomas, D.M. (2019). Infiltrating myeloid cells drive osteosarcoma progression via GRM4 regulation of IL23. Cancer Discov, 9: 1511-1519.
35 Best MC, Bartley N, Jacobs C, Juraskova I, Goldstien D, Newson AJ, Savard J, Meiser B, Ballinger ML, Napier C, Thomas DM, Biesecker B, Butow P and members of the PiGeOn Project (2019). Patient perspectives on molecular tumour profiling: “Why wouldn’t you?”. BMC Cancer 19:753.
34 Thavaneswaran S, Rath E, Tucker K, Joshua AM, Hess D, Pinese M, Ballinger ML and Thomas DM (2019). Therapeutic implications of germline genetic findings in cancer. Nat Rev Clin Oncol 16: 386-396.
33 McCabe MJ, Pinese M, Chan CL, Sheriff N, Thompson TJ, Grady J, Wong M, Gauthier MA, Puttick C, Gayevskiy V, Hajdu E, Wong SQ, Barrett W, Earls P, Lukeis R, Cheng YY, Lin RCY, Thomas DM, Watkins DN, Dinger ME, McCormack AI and Cowley MJ (2019). Genomic stratification and liquid biopsy in a rare adrenocortical carcinoma (ACC) case, with dual lung metastases. Cold Spring Harb Mol Case Stud 5: pii: a003764.
32 Lacaze P, Pinese M, Kaplan W, Stone A, Brion MJ, Woods RL, McNamara M, McNeil JJ, Dinger ME and Thomas DM (2019). The Medical Genome Reference Bank: a whole-genome data resource of 4000 healthy elderly individuals. Rationale and cohort design. European Journal of Human Genetics 27: 308-316.
31 Jones RM, Melton PE, Pinese M, Rea AJ, Ingley E, Ballinger ML, Wood DJ, Thomas DM and Moses EK (2019). Identification of novel sarcoma risk genes using a two-stage genome wide DNA sequencing strategy in cancer cluster families and population case and control cohorts. BMC Med Genet 20: 69.
30 Heyer EE, Deveson IW, Wooi D, Selinger CI, Lyons RJ, Hayes VM, O’Toole SA, Ballinger ML, Gill D, Thomas DM, Mercer TR and Blackburn J (2019). Diagnosis of fusion genes using targeted RNA sequencing. Nat Commun 10: 1388.
29 Fortuno C, Cipponi A, Ballinger ML, Tavtigian SV, Olivier M, Ruparel V, Haupt Y, Haupt S, Study ISK, Tucker K, Spurdle AB, Thomas DM and James PA (2019). A quantitative model to predict pathogenicity of missense variants in the TP53 gene. Hum Mutat 40: 788-800.
28 Ballinger ML, Pinese M and Thomas DM (2019). Translating genomic risk into an early detection strategy for sarcoma. Genes Chromosomes Cancer 58: 130-136.
27 Malkin D, Bond G, Thomas DM, Ballinger ML, World Health Organisation Classification of Tumours – Soft Tissue and Bone 5th edition, 2019. Li Fraumeni Syndrome.


26 Zilberg, C., Lee, M.W., Yu, B., Ashford, B., Kraitsek, S., Ranson, M., Shannon, K., Cowley, M., Iyer, N.G., Palme, C.E., Ch’ng, S., Low, T.H., O’Toole, S., Clark, J.R., Gupta, R. 2018 Analysis of clinically relevant somatic mutations in high-risk head and neck cutaneous squamous cell carcinoma. Mod Pathol, 31: 275-287.
25 Woodcock, F., Doble, B., Cancer 2015 Consortium*. 2018 Mapping the EORTC-QLQ-C30 to the EQ- 5D-3L: An Assessment of Existing and Newly Developed Algorithms. Med Decis Making, 38: 954-967. (*D Thomas Chief Investigator)
24 Walczak, A., Patterson, P., Thomas, D. 2018 Trials and tribulations: improving outcomes for adolescents and young adults with rare and low survival cancers. Med J Aust, 209: 330-332.
23 Thavaneswaran, S., Sebastian, L., Ballinger, M., Best, M., Hess, D., Lee, C.K., Sjoquist, K.M., Hague, W.E., Butow, P.N., Simes, R.J., Thomas, D. 2018 Cancer Molecular Screening and Therapeutics (MoST): a framework for multiple, parallel signal-seeking studies of targeted therapies for rare and neglected cancers. Med J Aust, 209: 354-355.
22 Rasmussen, V., Forrest, L.E., Rogasik, M., Girodet, M., Meeus, P., Sunyach, M.P., Blay, J.Y., Bally, O., Brahmi, M., Ballinger, M.L., Niedermayr, E., Thomas, D.M., Halliday, J., James, P., Ray-Coquard, I., Young, M.A., International Sarcoma Kindred, S. 2018 A comparison of Australian and French families affected by sarcoma: perceptions of genetics and incidental findings. Per Med, 15: 13-24.
21 Koster, R., Panagiotou, O.A., Wheeler, W.A., Karlins, E., Gastier-Foster, J.M., Caminada de Toledo, S.R., Petrilli, A.S., Flanagan, A.M., Tirabosco, R., Andrulis, I.L., Wunder, J.S., Gokgoz, N., Patino-Garcia, A., Lecanda, F., Serra, M., Hattinger, C., Picci, P., Scotlandi, K., Thomas, D.M., Ballinger, M.L., Gorlick, R., Barkauskas, D.A., Spector, L.G., Tucker, M., Belynda, D.H., Yeager, M., Hoover, R.N., Wacholder, S., Chanock, S.J., Savage, S.A., Mirabello, L. 2018 Genome-wide association study identifies the GLDC/IL33 locus associated with survival of osteosarcoma patients. Int J Cancer, 142: 1594-1601.
20 Gounder, M.M., Thomas, D.M., Tap, W.D. 2018 Locally aggressive connective tissue tumors. J Clin Oncol, 36: 202-209.
19 Chou, A., Froio, D., Nagrial, A.M., Parkin, A., Murphy, K.J., Chin, V.T., Wohl, D., Steinmann, A., Stark, R., Drury, A., Walters, S.N., Vennin, C., Burgess, A., Pinese, M., Chantrill, L.A., Cowley, M.J., Molloy, T.J., Waddell, N., Johns, A., Grimmond, S.M., Chang, D.K., Biankin, A.V., Sansom, O.J., Morton, J.P., Grey, S.T., Cox, T.R., Turchini, J., Samra, J., Clarke, S.J., Timpson, P., Gill, A.J., Pajic, M. 2018 Tailored first-line and second-line CDK4-targeting treatment combinations in mouse models of pancreatic cancer. Gut, 67: 2142-2155.
18 Best, M., Newson, A.J., Meiser, B., Juraskova, I., Goldstein, D., Tucker, K., Ballinger, M.L., Hess, D., Schlub, T.E., Biesecker, B., Vines, R., Vines, K., Thomas, D., Young, M.A., Savard, J., Jacobs, C., Butow, P. 2018 The PiGeOn project: protocol of a longitudinal study examining psychosocial and ethical issues and outcomes in germline genomic sequencing for cancer. BMC Cancer, 18: 454.
17 Best, M., Newson, A.J., Meiser, B., Juraskova, I., Goldstein, D., Tucker, K., Ballinger, M.L., Hess, D., Schlub, T.E., Biesecker, B., Vines, R., Vines, K., Thomas, D., Young, M.A., Savard, J., Jacobs, C., Butow, P. 2018 The PiGeOn project: protocol for a longitudinal study examining psychosocial, behavioural and ethical issues and outcomes in cancer tumour genomic profiling. BMC Cancer, 18: 389.
16 Lacaze, P., Pinese, M., Kaplan, W., Stone, A., Brion, M.J., Woods, R.L., McNamara, M., McNeil, J.J., Dinger, M.E., Thomas, D.M. 2018 The Medical Genome Reference Bank: a whole-genome data resource of 4000 healthy elderly individuals. Rationale and cohort design. Eur J Hum Genet, doi: 10.1038/s41431- 41018-40279-z.


15 Willis, A.M., Smith, S.K., Meiser, B., Ballinger, M.L., Thomas, D.M., Young, M.A. 2017 Sociodemographic, psychosocial and clinical factors associated with uptake of genetic counseling for hereditary cancer: a systematic review. Clin Genet, 92: 121-133.
14 Warton, K., Yuwono, N.L., Cowley, M.J., McCabe, M.J., So, A., Ford, C.E. 2017 Evaluation of Streck BCT and PAXgene stabilised blood collection tubes for cell-free circulating DNA studies in plasma. Mol Diagn Ther, 21: 563-570.
13 Thomas, D.M., Whelan, J. in Cancer in Adolescents and Young Adults. Pediatric Oncology (eds. Bleyer, A., Barr, R., Ries, L., Whelan, J. & Ferrari, A.) 417-427 (Springer International Publishing, 2017).
12 Thomas, D.M. 2017 Is Li-Fraumeni syndrome really much more common? Hum Mutat, 38: 1619.
11 Takeda, K., Nakayama, M., Hayakawa, Y., Kojima, Y., Ikeda, H., Imai, N., Ogasawara, K., Okumura, K., Thomas, D.M., Smyth, M.J. 2017 IFN-gamma is required for cytotoxic T cell-dependent cancer genome immunoediting. Nat Commun, 8: 14607.
10 Peng, G., Bojadzieva, J., Ballinger, M.L., Li, J., Blackford, A.L., Mai, P.L., Savage, S.A., Thomas, D.M., Strong, L.C., Wang, W. 2017 Estimating TP53 mutation carrier probability in families with Li-Fraumeni syndrome using LFSPRO. Cancer Epidemiol Biomarkers Prev, 26: 837-844.
9 McBride, K.A., Ballinger, M.L., Schlub, T.E., Young, M.A., Tattersall, M.H., Kirk, J., Eeles, R., Killick, E., Walker, L.G., Shanley, S., Thomas, D.M., Mitchell, G. 2017 Psychosocial morbidity in TP53 mutation carriers: is whole-body cancer screening beneficial? Fam Cancer, 16: 423-432.
8 Lorgelly, P.K., Doble, B., Rowen, D., Brazier, J., Cancer 2015 Investigators*. 2017 Condition-specific or generic preference-based measures in oncology? A comparison of the EORTC-8D and the EQ-5D-3L. Qual Life Res, 26: 1163-1176. (*D Thomas Chief Investigator)
7 Leroy, B., Ballinger, M.L., Baran-Marszak, F., Bond, G.L., Braithwaite, A., Concin, N., Donehower, L.A., El-Deiry, W.S., Fenaux, P., Gaidano, G., Langerod, A., Hellstrom-Lindberg, E., Iggo, R., Lehmann-Che, J., Mai, P.L., Malkin, D., Moll, U.M., Myers, J.N., Nichols, K.E., Pospisilova, S., Ashton-Prolla, P., Rossi, D., Savage, S.A., Strong, L.C., Tonin, P.N., Zeillinger, R., Zenz, T., Fraumeni, J.F., Jr., Taschner, P.E., Hainaut, P., Soussi, T. 2017 Recommended guidelines for validation, quality control, and reporting of TP53 variants in clinical practice. Cancer Res, 77: 1250-1260.
6 Khoo, T.K., Yu, B., Smith, J.A., Clarke, A.J., Luk, P.P., Selinger, C.I., Mahon, K.L., Kraitsek, S., Palme, C., Boyer, M.J., Dinger, M.E., Cowley, M.J., O’Toole, S.A., Clark, J.R., Gupta, R. 2017 Somatic mutations in salivary duct carcinoma and potential therapeutic targets. Oncotarget, 8: 75893-75903.
5 Fleuren, E.D.G., Vlenterie, M., van der Graaf, W., Hillebrandt-Roeffen, M.H.S., Blackburn, J., Ma, X., Chan, H., Magias, M.C., van Erp, A., van Houdt, L., Cebeci, S., van de Ven, A., Flucke, U.E., Heyer, E.E., Thomas, D.M., Lord, C.J., Marini, K.D., Vaghjiani, V., Mercer, T., Cain, J.E., Wu, J., Versleijen-Jonkers, Y.M.H., Daly, R.J. 2017 Phosphoproteomic profiling reveals ALK and MET as novel actionable targets across synovial sarcoma subtypes. Cancer Res, 77: 4279-4292.
4 Doble, B., John, T., Thomas, D., Fellowes, A., Fox, S., Lorgelly, P. 2017 Cost-effectiveness of precision medicine in the fourth-line treatment of metastatic lung adenocarcinoma: An early decision analytic model of multiplex targeted sequencing. Lung Cancer, 107: 22-35.
3 Cho, D., Roncolato, F.T., Man. J., Simes, J., Lord, S.J., Links, M.J., Lee, C.K. 2017 Clinical equipoise for trials of novel biological therapies, therapeutic success rates and predictors of success: a meta-analysis. JCO Prec Oncol 1:1-12
2 Ballinger, M.L., Ferris, N.J., Moodie, K., Mitchell, G., Shanley, S., James, P.A., Thomas, D.M. 2017 Surveillance in germline TP53 mutation carriers utilizing whole-body magnetic resonance imaging. JAMA Oncol, 3: 1735-1736.
1 Ballinger, M.L., Best, A., Mai, P.L., Khincha, P.P., Loud, J.T., Peters, J.A., Achatz, M.I., Chojniak, R., Balieiro da Costa, A., Santiago, K.M., Garber, J., O’Neill, A.F., Eeles, R.A., Evans, D.G., Bleiker, E., Sonke, G.S., Ruijs, M., Loo, C., Schiffman, J., Naumer, A., Kohlmann, W., Strong, L.C., Bojadzieva, J., Malkin, D., Rednam, S.P., Stoffel, E.M., Koeppe, E., Weitzel, J.N., Slavin, T.P., Nehoray, B., Robson, M., Walsh, M., Manelli, L., Villani, A., Thomas, D.M., Savage, S.A. 2017 Baseline surveillance in Li-Fraumeni syndrome using whole-body magnetic resonance imaging: a meta-analysis. JAMA Oncol, 3: 1634-1639.